Polyamine Metabolism for Drug Intervention in Trypanosomatids
暂无分享,去创建一个
Y. Pérez-Pertejo | C. García-Estrada | R. Balaña-Fouce | M. Martínez-Valladares | Rosa M. Reguera | Sankaranarayanan Murugesan
[1] Rajiv Kumar,et al. Post kala-azar dermal leishmaniasis in the Indian sub-continent: challenges and strategies for elimination , 2023, Frontiers in immunology.
[2] A. Edkins,et al. Tackling Sleeping Sickness: Current and Promising Therapeutics and Treatment Strategies , 2023, International journal of molecular sciences.
[3] J. van Griensven,et al. The status of combination therapy for visceral leishmaniasis: an updated review. , 2023, The Lancet. Infectious diseases.
[4] T. Agampodi,et al. The stigma associated with cutaneous leishmaniasis (CL) and mucocutaneous leishmaniasis (MCL): A protocol for a systematic review , 2023, PloS one.
[5] A. Hofer. Targeting the nucleotide metabolism of Trypanosoma brucei and other trypanosomatids , 2023, FEMS microbiology reviews.
[6] Ancheng C. Huang,et al. Conformational cycle of human polyamine transporter ATP13A2 , 2023, Nature Communications.
[7] Adarsh Vardhan Tangella,et al. Difluoromethylornithine (DFMO) and Neuroblastoma: A Review , 2023, Cureus.
[8] Y. Pérez-Pertejo,et al. Further Investigations of Nitroheterocyclic Compounds as Potential Antikinetoplastid Drug Candidates , 2023, Biomolecules.
[9] S. Montgomery,et al. Chagas Disease , 2023, Annals of Internal Medicine.
[10] A. Ilari,et al. Inhibition of Leishmania infantum Trypanothione Reductase by New Aminopropanone Derivatives Interacting with the NADPH Binding Site , 2023, Molecules.
[11] Y. Pérez-Pertejo,et al. Miltefosine and Nifuratel Combination: A Promising Therapy for the Treatment of Leishmania donovani Visceral Leishmaniasis , 2023, International journal of molecular sciences.
[12] Lucas N. Alberca,et al. A combined ligand and target-based virtual screening strategy to repurpose drugs as putrescine uptake inhibitors with trypanocidal activity , 2022, Journal of Computer-Aided Molecular Design.
[13] David Shum,et al. Discovery of novel Leishmania major trypanothione synthetase inhibitors by high-throughput screening. , 2022, Biochemical and biophysical research communications.
[14] E. Bottieau,et al. Gambiense human African trypanosomiasis: the bumpy road to elimination , 2022, Current opinion in infectious diseases.
[15] Prof Vikas Kumar,et al. - Amphotericin B: A drug of choice for Visceral Leishmaniasis. , 2022, Acta tropica.
[16] Surbhi Jain,et al. Metabolic Pathways of Leishmania Parasite: Source of Pertinent Drug Targets and Potent Drug Candidates , 2022, Pharmaceutics.
[17] Pravindra Kumar,et al. Biophysical and modeling-based approach for the identification of inhibitors against DOHH from Leishmania donovani. , 2022, Briefings in functional genomics.
[18] A. Ilari,et al. Innovative Approach for a Classic Target: Fragment Screening on Trypanothione Reductase Reveals New Opportunities for Drug Design , 2022, Frontiers in Molecular Biosciences.
[19] P. Chiodini,et al. Diagnosis and Clinical Management of Chagas Disease: An Increasing Challenge in Non-Endemic Areas , 2022, Research and reports in tropical medicine.
[20] N. Carter,et al. Polyamine Metabolism in Leishmania Parasites: A Promising Therapeutic Target , 2022, Medical sciences.
[21] David Shum,et al. Drug-like molecules with anti-trypanothione synthetase activity identified by high throughput screening , 2022, Journal of enzyme inhibition and medicinal chemistry.
[22] H. Bergman,et al. Chemotherapy for second‐stage human African trypanosomiasis: drugs in use , 2021, The Cochrane database of systematic reviews.
[23] J. Beijnen,et al. An update on the clinical pharmacology of miltefosine in the treatment of leishmaniasis. , 2021, International journal of antimicrobial agents.
[24] T. Mavromoustakos,et al. An Overview on Target-Based Drug Design against Kinetoplastid Protozoan Infections: Human African Trypanosomiasis, Chagas Disease and Leishmaniases , 2021, Molecules.
[25] M. Meenu,et al. The discovery of indolone GW5074 during a comprehensive search for non-polyamine-based polyamine transport inhibitors. , 2021, The international journal of biochemistry & cell biology.
[26] C. Baroukh,et al. Polyamines: double agents in disease and plant immunity. , 2021, Trends in plant science.
[27] A. Kopylov,et al. The Concept of Folic Acid in Health and Disease , 2021, Molecules.
[28] J. Albrecht,et al. Roles of nitric oxide and polyamines in brain tumor growth. , 2021, Advances in medical sciences.
[29] Rachel Tidman,et al. The impact of climate change on neglected tropical diseases: a systematic review , 2021, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[30] M. Bijlmakers. Ubiquitination and the Proteasome as Drug Targets in Trypanosomatid Diseases , 2021, Frontiers in Chemistry.
[31] O. Singh,et al. Domestic Mammals as Reservoirs for Leishmania donovani on the Indian Subcontinent: Possibility and Consequences on Elimination. , 2020, Transboundary and emerging diseases.
[32] V. Baekelandt,et al. ATP13A3 is a major component of the enigmatic mammalian polyamine transport system , 2020, The Journal of biological chemistry.
[33] C. Robello,et al. Trypanothione metabolism as Drug Target for Trypanosomatids. , 2020, Current pharmaceutical design.
[34] P. Z. Ramos,et al. Structural features and development of an assay platform of the parasite target deoxyhypusine synthase of Brugia malayi and Leishmania major , 2020, PLoS neglected tropical diseases.
[35] R. Banerjee,et al. In vivo experiments demonstrate the potent antileishmanial efficacy of repurposed suramin in visceral leishmaniasis , 2020, PLoS neglected tropical diseases.
[36] F. Supek,et al. Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of Leishmaniases , 2020, Journal of medicinal chemistry.
[37] S. Raj,et al. An overview of biochemically characterized drug targets in metabolic pathways of Leishmania parasite , 2020, Parasitology Research.
[38] S. Harper,et al. Spiro-containing derivatives show antiparasitic activity against Trypanosoma brucei through inhibition of the trypanothione reductase enzyme , 2020, PLoS neglected tropical diseases.
[39] Zhong-dao Wu,et al. Human African trypanosomiasis: the current situation in endemic regions and the risks for non-endemic regions from imported cases , 2020, Parasitology.
[40] Sen Liu,et al. Repurposing Clinical Drugs as AdoMetDC Inhibitors Using the SCAR Strategy , 2020, Frontiers in Pharmacology.
[41] S. Pantano,et al. Mechanistic and biological characterisation of novel N5-substituted paullones targeting the biosynthesis of trypanothione in Leishmania , 2020, Journal of enzyme inhibition and medicinal chemistry.
[42] Chantal Reigada,et al. Identification of Trypanosoma cruzi Polyamine Transport Inhibitors by Computational Drug Repurposing , 2019, Front. Med..
[43] L. Tilley,et al. The proteasome as a target for protozoan parasites , 2019, Expert opinion on therapeutic targets.
[44] C. García-Estrada,et al. DNA Topoisomerases of Leishmania parasites; druggable targets for drug discovery. , 2019, Current medicinal chemistry.
[45] R. Castillo,et al. Leishmania mexicana Trypanothione Reductase Inhibitors: Computational and Biological Studies , 2019, Molecules.
[46] S. Croft,et al. Route map for the discovery and pre-clinical development of new drugs and treatments for cutaneous leishmaniasis , 2019, International journal for parasitology. Drugs and drug resistance.
[47] S. Sundar,et al. Current and emerging medications for the treatment of leishmaniasis , 2019, Expert opinion on pharmacotherapy.
[48] M. Gramiccia,et al. Structure-guided approach to identify a novel class of anti-leishmaniasis diaryl sulfide compounds targeting the trypanothione metabolism , 2019, Amino Acids.
[49] Maria Paola Costi,et al. Structural Insights into the Development of Cycloguanil Derivatives as Trypanosoma brucei Pteridine-Reductase-1 Inhibitors. , 2019, ACS infectious diseases.
[50] M. Phillips,et al. Trypanosomatid Deoxyhypusine Synthase Activity Is Dependent on Shared Active-Site Complementation between Pseudoenzyme Paralogs. , 2018, Structure.
[51] A. Pegg. Introduction to the Thematic Minireview Series: Sixty plus years of polyamine research , 2018, The Journal of Biological Chemistry.
[52] M. Phillips. Polyamines in protozoan pathogens , 2018, The Journal of Biological Chemistry.
[53] M. Phillips,et al. A dual regulatory circuit consisting of S-adenosylmethionine decarboxylase protein and its reaction product controls expression of the paralogous activator prozyme in Trypanosoma brucei , 2018, PLoS pathogens.
[54] A. Pegg,et al. Polyamine metabolism and cancer: treatments, challenges and opportunities , 2018, Nature Reviews Cancer.
[55] I. Felzenszwalb,et al. Repurposing Strategy of Atorvastatin against Trypanosoma cruzi: In Vitro Monotherapy and Combined Therapy with Benznidazole Exhibit Synergistic Trypanocidal Activity , 2018, Antimicrobial Agents and Chemotherapy.
[56] S. Sundar,et al. Emerging therapeutic targets for treatment of leishmaniasis , 2018, Expert opinion on therapeutic targets.
[57] S. Burza,et al. Leishmaniasis , 2018, The Lancet.
[58] M. Booth. Climate Change and the Neglected Tropical Diseases , 2018, Advances in Parasitology.
[59] A. M. Carvalho,et al. The Elderly Respond to Antimony Therapy for Cutaneous Leishmaniasis Similarly to Young Patients but Have Severe Adverse Reactions. , 2018, The American journal of tropical medicine and hygiene.
[60] Chantal Reigada,et al. Targeting polyamine transport in Trypanosoma cruzi. , 2018, European journal of medicinal chemistry.
[61] N. LoGiudice,et al. Alpha-Difluoromethylornithine, an Irreversible Inhibitor of Polyamine Biosynthesis, as a Therapeutic Strategy against Hyperproliferative and Infectious Diseases , 2018, Medical sciences.
[62] L. Floeter-Winter,et al. Arginine and Polyamines Fate in Leishmania Infection , 2018, Front. Microbiol..
[63] M. Phillips,et al. Species-Selective Pyrimidineamine Inhibitors of Trypanosoma brucei S-Adenosylmethionine Decarboxylase. , 2018, Journal of medicinal chemistry.
[64] S. Sundar,et al. Chemotherapeutics of visceral leishmaniasis: present and future developments , 2017, Parasitology.
[65] L. Floeter-Winter,et al. Arginase expression modulates nitric oxide production in Leishmania (Leishmania) amazonensis , 2017, PloS one.
[66] T. E. Richardson,et al. Synthesis and evaluation of analogs of 5'-(((Z)-4-amino-2-butenyl)methylamino)-5'-deoxyadenosine (MDL 73811, or AbeAdo) - An inhibitor of S-adenosylmethionine decarboxylase with antitrypanosomal activity. , 2017, Bioorganic & medicinal chemistry.
[67] D. Horn,et al. Ornithine uptake and the modulation of drug sensitivity in Trypanosoma brucei , 2017, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[68] T. E. Richardson,et al. Identification of Trypanosoma brucei AdoMetDC Inhibitors Using a High-Throughput Mass Spectrometry-Based Assay. , 2017, ACS infectious diseases.
[69] A. Errasti,et al. Trypanocidal Effect of Isotretinoin through the Inhibition of Polyamine and Amino Acid Transporters in Trypanosoma cruzi , 2017, PLoS neglected tropical diseases.
[70] D. Boykin,et al. In Vitro, Ex Vivo, and In Vivo Activities of Diamidines against Trypanosoma congolense and Trypanosoma vivax , 2017, Antimicrobial Agents and Chemotherapy.
[71] A. Iglesias,et al. Rational design of nitrofuran derivatives: Synthesis and valuation as inhibitors of Trypanosoma cruzi trypanothione reductase. , 2017, European journal of medicinal chemistry.
[72] N. Grishin,et al. Relief of autoinhibition by conformational switch explains enzyme activation by a catalytically dead paralog , 2016, eLife.
[73] P. Yates,et al. Arginase Is Essential for Survival of Leishmania donovani Promastigotes but Not Intracellular Amastigotes , 2016, Infection and Immunity.
[74] Glen Spraggon,et al. Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness , 2016, Nature.
[75] A. Aly,et al. Plasmodium AdoMetDC/ODC bifunctional enzyme is essential for male sexual stage development and mosquito transmission , 2016, Biology Open.
[76] P. Yates,et al. The Polyamine Pathway of Leishmania donovani as a Potential Therapeutic Target , 2016, The FASEB Journal.
[77] S. Sundar,et al. Comparative Analysis of Cellular Immune Responses in Treated Leishmania Patients and Hamsters against Recombinant Th1 Stimulatory Proteins of Leishmania donovani , 2016, Front. Microbiol..
[78] Darío E. Balcazar,et al. Trypanosoma cruzi Polyamine Transporter: Its Role on Parasite Growth and Survival Under Stress Conditions , 2016, The Journal of Membrane Biology.
[79] V. Dubey,et al. Novel Inhibitors of Ornithine Decarboxylase of Leishmania Parasite (LdODC): The Parasite Resists LdODC Inhibition by Overexpression of Spermidine Synthase , 2016, Chemical biology & drug design.
[80] Alan Talevi,et al. Discovery of novel polyamine analogs with anti-protozoal activity by computer guided drug repositioning , 2016, Journal of Computer-Aided Molecular Design.
[81] D. Leaver,et al. Fluorinated Sterols Are Suicide Inhibitors of Ergosterol Biosynthesis and Growth in Trypanosoma brucei. , 2015, Chemistry & biology.
[82] T. Niimi,et al. Structural insights into the novel inhibition mechanism of Trypanosoma cruzi spermidine synthase. , 2015, Acta crystallographica. Section D, Biological crystallography.
[83] Sushma R. Singh,et al. Antileishmanial effect of mevastatin is due to interference with sterol metabolism , 2015, Parasitology Research.
[84] M. Miles,et al. Between a bug and a hard place: Trypanosoma cruzi genetic diversity and the clinical outcomes of Chagas disease , 2015, Expert review of anti-infective therapy.
[85] Megan P. Miller,et al. Identification and functional characterization of a novel arginine/ornithine transporter, a member of a cationic amino acid transporter subfamily in the Trypanosoma cruzi genome , 2015, Parasites & Vectors.
[86] J. Correa-Basurto,et al. Design, synthesis and biological evaluation of quinazoline derivatives as anti-trypanosomatid and anti-plasmodial agents. , 2015, European journal of medicinal chemistry.
[87] Jorge González,et al. Role of the Ubiquitin-Proteasome Systems in the Biology and Virulence of Protozoan Parasites , 2015, BioMed research international.
[88] J. Pratap,et al. Novel protein-protein interaction between spermidine synthase and S-adenosylmethionine decarboxylase from Leishmania donovani. , 2015, Biochemical and biophysical research communications.
[89] M. Barrett,et al. Crystal Structure of an Arginase-like Protein from Trypanosoma brucei That Evolved without a Binuclear Manganese Cluster , 2014, Biochemistry.
[90] C. García-Estrada,et al. Trypanosomatids topoisomerase re-visited. New structural findings and role in drug discovery , 2014, International journal for parasitology. Drugs and drug resistance.
[91] S. Sundar,et al. Characterization of Glycolytic Enzymes - rAldolase and rEnolase of Leishmania donovani, Identified as Th1 Stimulatory Proteins, for Their Immunogenicity and Immunoprophylactic Efficacies against Experimental Visceral Leishmaniasis , 2014, PloS one.
[92] Montserrat G. Vásquez-Valdivieso,et al. Identification of ML251, a Potent Inhibitor of T. brucei and T. cruzi Phosphofructokinase. , 2014, ACS medicinal chemistry letters.
[93] R. B. Giordani,et al. Assessment of Leishmanicidal and Trypanocidal Activities of Aliphatic Diamine Derivatives , 2013, Chemical biology & drug design.
[94] H. Wallace,et al. Polyamines and membrane transporters , 2013, Amino Acids.
[95] M. Phillips,et al. Product feedback regulation implicated in translational control of the Trypanosoma brucei S‐adenosylmethionine decarboxylase regulatory subunit prozyme , 2013, Molecular microbiology.
[96] M. Strauss,et al. Use of clomipramine as chemotherapy of the chronic phase of Chagas disease , 2013, Parasitology.
[97] A. Fairlamb,et al. Allosteric Activation of Trypanosomatid Deoxyhypusine Synthase by a Catalytically Dead Paralog , 2013, The Journal of Biological Chemistry.
[98] C. Rock,et al. Role of dietary polyamines in a phase III clinical trial of difluoromethylornithine (DFMO) and sulindac for prevention of sporadic colorectal adenomas , 2013, British Journal of Cancer.
[99] M. Phillips,et al. Trypanosoma brucei S-Adenosylmethionine Decarboxylase N Terminus Is Essential for Allosteric Activation by the Regulatory Subunit Prozyme* , 2013, The Journal of Biological Chemistry.
[100] N. Carter,et al. Purine salvage in Leishmania: complex or simple by design? , 2012, Trends in parasitology.
[101] Michael P. Barrett,et al. Untargeted Metabolomics Reveals a Lack Of Synergy between Nifurtimox and Eflornithine against Trypanosoma brucei , 2012, PLoS neglected tropical diseases.
[102] L. Floeter-Winter,et al. Leishmania amazonensis Arginase Compartmentalization in the Glycosome Is Important for Parasite Infectivity , 2012, PloS one.
[103] R. Madhubala,et al. A Unique Modification of the Eukaryotic Initiation Factor 5A Shows the Presence of the Complete Hypusine Pathway in Leishmania donovani , 2012, PloS one.
[104] Y. Pérez-Pertejo,et al. Role of trypanosomatid's arginase in polyamine biosynthesis and pathogenesis. , 2012, Molecular and biochemical parasitology.
[105] B. Miniscalco,et al. Canine leishmaniosis: in vitro efficacy of miltefosine and marbofloxacin alone or in combination with allopurinol against clinical strains of Leishmania infantum , 2012, Parasitology Research.
[106] V. Dubey,et al. Cloning, expression, characterization and inhibition studies on trypanothione synthetase, a drug target enzyme, from Leishmania donovani , 2011, Biological chemistry.
[107] T. Vickers,et al. Folate metabolic pathways in Leishmania. , 2011, Essays in biochemistry.
[108] P. Fernandes,et al. Mechanism of formation of the internal aldimine in pyridoxal 5'-phosphate-dependent enzymes. , 2011, Journal of the American Chemical Society.
[109] Y. Pérez-Pertejo,et al. Leishmania donovani: proteasome-mediated down-regulation of methionine adenosyltransferase , 2011, Parasitology.
[110] B. Ullman,et al. Spermidine Synthase Is Required for Virulence of Leishmania donovani , 2011, Infection and Immunity.
[111] M. Morris,et al. Glycolysis in the African Trypanosome: Targeting Enzymes and Their Subcellular Compartments for Therapeutic Development , 2011, Molecular biology international.
[112] Yves Pommier,et al. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. , 2010, Chemistry & biology.
[113] F. Chappuis,et al. NECT Is Next: Implementing the New Drug Combination Therapy for Trypanosoma brucei gambiense Sleeping Sickness , 2010, PLoS neglected tropical diseases.
[114] C. Carrillo,et al. Trypanosoma cruzi amino acid transporter TcAAAP411 mediates arginine uptake in yeasts. , 2010, FEMS microbiology letters.
[115] I. Coppens,et al. A high‐affinity putrescine‐cadaverine transporter from Trypanosoma cruzi , 2010, Molecular microbiology.
[116] S. Valentini,et al. Functional significance of eIF5A and its hypusine modification in eukaryotes , 2010, Amino Acids.
[117] W. Hunter,et al. Structure-Based Design of Pteridine Reductase Inhibitors Targeting African Sleeping Sickness and the Leishmaniases† , 2009, Journal of medicinal chemistry.
[118] R. Madhubala,et al. Identification and Characterization of a Novel Deoxyhypusine Synthase in Leishmania donovani* , 2009, The Journal of Biological Chemistry.
[119] W. de Souza,et al. Sterol Biosynthesis Pathway as Target for Anti-trypanosomatid Drugs , 2009, Interdisciplinary perspectives on infectious diseases.
[120] R. Barker,et al. Trypanocidal Activity of 8-Methyl-5′-{[(Z)-4-Aminobut-2-enyl]-(Methylamino)}Adenosine (Genz-644131), an Adenosylmethionine Decarboxylase Inhibitor , 2009, Antimicrobial Agents and Chemotherapy.
[121] D. Rentsch,et al. Arginine Homeostasis and Transport in the Human Pathogen Leishmania donovani* , 2009, The Journal of Biological Chemistry.
[122] R. Balaña-Fouce,et al. Leishmania major lacking arginase (ARG) are auxotrophic for polyamines but retain infectivity to susceptible BALB/c mice. , 2009, Molecular and biochemical parasitology.
[123] M. Phillips,et al. RNA Interference-Mediated Silencing of Ornithine Decarboxylase and Spermidine Synthase Genes in Trypanosoma brucei Provides Insight into Regulation of Polyamine Biosynthesis , 2009, Eukaryotic Cell.
[124] M. Wilson,et al. Leishmania donovani Ornithine Decarboxylase Is Indispensable for Parasite Survival in the Mammalian Host , 2008, Infection and Immunity.
[125] M. Phillips,et al. Regulated Expression of an Essential Allosteric Activator of Polyamine Biosynthesis in African Trypanosomes , 2008, PLoS pathogens.
[126] M. Vannier-Santos,et al. The putrescine analogue 1,4-diamino-2-butanone affects polyamine synthesis, transport, ultrastructure and intracellular survival in Leishmania amazonensis. , 2008, Microbiology.
[127] H. Kaur,et al. Validation of spermidine synthase as a drug target in African trypanosomes. , 2008, The Biochemical journal.
[128] M. Wilson,et al. An Effect of Parasite-Encoded Arginase on the Outcome of Murine Cutaneous Leishmaniasis1 , 2007, The Journal of Immunology.
[129] O. Heby,et al. Targeting the polyamine biosynthetic enzymes: a promising approach to therapy of African sleeping sickness, Chagas’ disease, and leishmaniasis , 2007, Amino Acids.
[130] J. Min,et al. Structure and mechanism of spermidine synthases. , 2007, Biochemistry.
[131] M. Phillips,et al. Allosteric regulation of an essential trypanosome polyamine biosynthetic enzyme by a catalytically dead homolog , 2007, Proceedings of the National Academy of Sciences.
[132] D. Roos,et al. Divergent polyamine metabolism in the Apicomplexa. , 2007, Microbiology.
[133] A. Pegg,et al. Polyamines and neoplastic growth. , 2007, Biochemical Society transactions.
[134] M. Walkinshaw,et al. The first crystal structure of phosphofructokinase from a eukaryote: Trypanosoma brucei. , 2007, Journal of molecular biology.
[135] L. Marton,et al. Leishmania donovani Polyamine Biosynthetic Enzyme Overproducers as Tools To Investigate the Mode of Action of Cytotoxic Polyamine Analogs , 2007, Antimicrobial Agents and Chemotherapy.
[136] Frédéric Bringaud,et al. Metabolic functions of glycosomes in trypanosomatids. , 2006, Biochimica et biophysica acta.
[137] R. Madhubala,et al. Antileishmanial Effect of 3-Aminooxy-1-Aminopropane Is Due to Polyamine Depletion , 2006, Antimicrobial Agents and Chemotherapy.
[138] Y. Pommier. Topoisomerase I inhibitors: camptothecins and beyond , 2006, Nature Reviews Cancer.
[139] G. E. Cánepa,et al. Molecular and functional characterization of a spermidine transporter (TcPAT12) from Trypanosoma cruzi. , 2006, Biochemical and biophysical research communications.
[140] D. Rentsch,et al. A novel high‐affinity arginine transporter from the human parasitic protozoan Leishmania donovani , 2006, Molecular microbiology.
[141] L. Aravind,et al. Molecular cloning, expression, and structural prediction of deoxyhypusine hydroxylase: a HEAT-repeat-containing metalloenzyme. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[142] A. Fairlamb,et al. Drug Resistance in Leishmaniasis , 2006, Clinical Microbiology Reviews.
[143] B. Ullman,et al. Identification and Characterization of a Polyamine Permease from the Protozoan Parasite Leishmania major* , 2005, Journal of Biological Chemistry.
[144] R. Reguera,et al. Polyamine transport in parasites: a potential target for new antiparasitic drug development. , 2005, Comparative biochemistry and physiology. Toxicology & pharmacology : CBP.
[145] Xin Hu,et al. Biological activity of the S-adenosylmethionine decarboxylase inhibitor SAM486A in human breast cancer cells in vitro and in vivo. , 2004, International journal of oncology.
[146] D. Davies,et al. A New Crystal Structure of Deoxyhypusine Synthase Reveals the Configuration of the Active Enzyme and of an Enzyme·NAD·Inhibitor Ternary Complex* , 2004, Journal of Biological Chemistry.
[147] Y. Pérez-Pertejo,et al. Mutational analysis of methionine adenosyltransferase from Leishmania donovani. , 2004, European journal of biochemistry.
[148] K. Gibson,et al. Arginase Plays a Pivotal Role in Polyamine Precursor Metabolism in Leishmania , 2004, Journal of Biological Chemistry.
[149] M. Avery,et al. Diamine derivatives with antiparasitic activities. , 2004, Bioorganic & medicinal chemistry letters.
[150] I. Gilbert,et al. Azasterols as inhibitors of sterol 24-methyltransferase in Leishmania species and Trypanosoma cruzi. , 2003, Journal of medicinal chemistry.
[151] C. Burri,et al. Eflornithine for the treatment of human African trypanosomiasis , 2003, Parasitology Research.
[152] D. Rice,et al. Fatty acid and sterol metabolism: potential antimicrobial targets in apicomplexan and trypanosomatid parasitic protozoa. , 2003, Molecular and biochemical parasitology.
[153] N. Carter,et al. S-adenosylmethionine decarboxylase from Leishmania donovani. Molecular, genetic, and biochemical characterization of null mutants and overproducers. , 2002, The Journal of biological chemistry.
[154] Y. Pérez-Pertejo,et al. Cloning Expression and Characterization of Methionine Adenosyltransferase in Leishmania infantumPromastigotes* , 2002, The Journal of Biological Chemistry.
[155] Shelly C. Lu,et al. S‐Adenosylmethionine: a control switch that regulates liver function , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[156] N. Biteau,et al. Molecular characterisation of mitochondrial and cytosolic trypanothione-dependent tryparedoxin peroxidases in Trypanosoma brucei. , 2001, Molecular and biochemical parasitology.
[157] P. Woster,et al. Novel alkylpolyamine analogues that possess both antitrypanosomal and antimicrosporidial activity. , 2001, Bioorganic & medicinal chemistry letters.
[158] S. Sundar,et al. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[159] K. Kashiwagi,et al. Properties of a polyamine transporter regulated by antizyme. , 2000, The Biochemical journal.
[160] S. Matsufuji,et al. Degradation of ornithine decarboxylase by the 26S proteasome. , 2000, Biochemical and biophysical research communications.
[161] C. Pereira,et al. L‐Arginine Uptake and L‐Phosphoarginine Synthesis In Trypanosoma Cruzi , 1999, The Journal of eukaryotic microbiology.
[162] I. Mathews,et al. The crystal structure of human S-adenosylmethionine decarboxylase at 2.25 A resolution reveals a novel fold. , 1999, Structure.
[163] A. Fairlamb,et al. Ornithine Decarboxylase Gene Deletion Mutants of Leishmania donovani * , 1999, The Journal of Biological Chemistry.
[164] J. Sufrin,et al. In vivo efficacies of 5'-methylthioadenosine analogs as trypanocides , 1997, Antimicrobial agents and chemotherapy.
[165] H. Mett,et al. Alterations in ornithine decarboxylase characteristics account for tolerance of Trypanosoma brucei rhodesiense to D,L-alpha-difluoromethylornithine , 1997, Antimicrobial agents and chemotherapy.
[166] Martin Olivier,et al. Disruption of the trypanothione reductase gene of Leishmania decreases its ability to survive oxidative stress in macrophages , 1997, The EMBO journal.
[167] R. Balaña-Fouce,et al. Effects of cationic diamidines on polyamine content and uptake on Leishmania infantum in in vitro cultures. , 1996, Biochemical pharmacology.
[168] S. Croft,et al. In vivo trypanocidal activities of new S-adenosylmethionine decarboxylase inhibitors , 1996, Antimicrobial agents and chemotherapy.
[169] V. Yardley,et al. In vitro trypanocidal activities of new S-adenosylmethionine decarboxylase inhibitors , 1996, Antimicrobial agents and chemotherapy.
[170] R. Kaminsky,et al. Innate lack of susceptibility of Ugandan Trypanosoma brucei rhodesiense to DL-alpha-difluoromethylornithine (DFMO). , 1995, Tropical medicine and parasitology : official organ of Deutsche Tropenmedizinische Gesellschaft and of Deutsche Gesellschaft fur Technische Zusammenarbeit.
[171] R. Reguera,et al. Fluorinated analogues of L-ornithine are powerful inhibitors of ornithine decarboxylase and cell growth of Leishmania infantum promastigotes. , 1994, Life sciences.
[172] D. V. Von Hoff. MGBG: teaching an old drug new tricks. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.
[173] R. Reguera,et al. Putrescine uptake inhibition by aromatic diamidines in Leishmania infantum promastigotes. , 1994, Biochemical pharmacology.
[174] A. Pegg,et al. Rapid exchange of subunits of mammalian ornithine decarboxylase. , 1994, The Journal of biological chemistry.
[175] A. Bitonti,et al. Cure of murine Trypanosoma brucei rhodesiense infections with an S-adenosylmethionine decarboxylase inhibitor , 1992, Antimicrobial Agents and Chemotherapy.
[176] L. Ghoda,et al. Structural elements of ornithine decarboxylase required for intracellular degradation and polyamine-dependent regulation , 1992, Molecular and cellular biology.
[177] A. Bitonti,et al. Cure of Trypanosoma brucei brucei and Trypanosoma brucei rhodesiense infections in mice with an irreversible inhibitor of S-adenosylmethionine decarboxylase , 1990, Antimicrobial Agents and Chemotherapy.
[178] M. Gramiccia,et al. In vivo effect of eflornithine (DFMO) and some related compounds on Leishmania infantum preliminary communication. , 1989, Farmaco.
[179] A. Cerami,et al. Chemotherapy of trypanosomiasis: the use of guanylhydrazone compounds in the treatment of experimental murine trypanosomiasis. , 1987, Tropical medicine and parasitology : official organ of Deutsche Tropenmedizinische Gesellschaft and of Deutsche Gesellschaft fur Technische Zusammenarbeit.
[180] A. Fairlamb,et al. In vivo effects of difluoromethylornithine on trypanothione and polyamine levels in bloodstream forms of Trypanosoma brucei. , 1987, Molecular and biochemical parasitology.
[181] R. Balaña-Fouce,et al. Inhibition of diamine oxidase and S-adenosylmethionine decarboxylase by diminacene aceturate (berenil). , 1986, Biochemical pharmacology.
[182] B. Chait,et al. Trypanothione: a novel bis(glutathionyl)spermidine cofactor for glutathione reductase in trypanosomatids. , 1985, Science.
[183] A. Bitonti,et al. Characterization of spermidine synthase from Trypanosoma brucei brucei. , 1984, Molecular and biochemical parasitology.
[184] P. McCann,et al. Polyamine metabolism: a potential therapeutic target in trypanosomes. , 1980, Science.
[185] A. Ilari,et al. Polyamine-trypanothione pathway: an update. , 2017, Future medicinal chemistry.
[186] Chagas disease in Latin America: an epidemiological update based on 2010 estimates. , 2015, Releve epidemiologique hebdomadaire.
[187] L. Floeter-Winter,et al. Arginase in Leishmania. , 2014, Sub-cellular biochemistry.
[188] D. Pace. Leishmaniasis. , 2014, The Journal of infection.
[189] V. Lutje,et al. Chemotherapy for second-stage Human African trypanosomiasis. , 2010, The Cochrane database of systematic reviews.
[190] Y. Pérez-Pertejo,et al. Characterization of a methionine adenosyltransferase over-expressing strain in the trypanosomatid Leishmania donovani. , 2006, Biochimica et biophysica acta.
[191] M. H. el Kouni. Potential chemotherapeutic targets in the purine metabolism of parasites. , 2003, Pharmacology & therapeutics.
[192] Héctor Villa,et al. Leishmania donovani methionine adenosyltransferase. Role of cysteine residues in the recombinant enzyme. , 2003, European journal of biochemistry.
[193] J. Champoux. DNA topoisomerases: structure, function, and mechanism. , 2001, Annual review of biochemistry.
[194] E. Gerner,et al. UC Irvine UC Irvine Previously Published Works Title Development of difluoromethylornithine ( DFMO ) as a chemoprevention agent , 2000 .
[195] R. Madhubala,et al. Antileishmanial effect of a potent S-adenosylmethionine decarboxylase inhibitor: CGP 40215A. , 1996, Pharmacological research.
[196] I. Coppens,et al. Activity, pharmacological inhibition and biological regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in Trypanosoma brucei. , 1995, Molecular and biochemical parasitology.
[197] A. Fairlamb,et al. Metabolism and functions of trypanothione in the Kinetoplastida. , 1992, Annual review of microbiology.